Marksans Pharma Ltd (NSE:MARKSANS)

Q3 2025 Marksans Pharma Ltd Earnings Call Transcript

Feb 12, 2025 / 12:00 PM GMT

Release Date Price: ₹254.21 (+1.03%)

Transcript

Key Points

Positve

Marksans Pharma Ltd (BOM:524404) reported an all-time high quarterly profit after tax (PAT) of INR 105 crores in Q3 FY25, marking a 26.6% year-on-year increase.
The company achieved a 16.3% year-on-year revenue growth in Q3 FY25, driven by strong performance in the US market, which grew by 37% year-on-year.
Gross profit increased by 22.4% year-on-year, with gross margins expanding by 279 basis points to 56.2% in Q3 FY25, aided by a better product mix and lower raw material prices.
Marksans Pharma Ltd (BOM:524404) remains debt-free with cash balances of INR 669 crores as of December 31, 2024, providing financial stability and flexibility.
The company is focused on strategic growth through new product launches and ramping up its new manufacturing facility, aiming for a revenue milestone of 3,000 crores.

Negative

The EBITDA margin for Q3 FY25 decreased by 234 basis points to 20.4%, primarily due to increased employee and freight costs.
Revenue from the Australia and New Zealand markets declined by 2.8% year-on-year, impacted by seasonality.
The rest of the world markets recorded lower revenue due to geopolitical issues, affecting overall performance.
The company faces potential risks from geopolitical uncertainties and possible tariff impositions, which could impact cost structures and pricing strategies.
Capacity utilization at the new manufacturing facility is currently low, around 20%, indicating underutilization and potential inefficiencies.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

MARK.NS - Marksans Pharma Ltd
Q3 2025 Marksans Pharma Ltd Earnings Call
Feb 12, 2025 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good day and welcome to Maxson's Pharma Q3 F 525 earnings conference call hosted by Elara Securities India Private Limited. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing, then 0 on attached and phone. Please note that this conference has been recorded.

I'm going to hand the contents over to Mr. Binno Fati Pariple from Alaa Securities India Private Limited.

Thank you and over to you, sir.

--------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.